S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

CLDX Celldex Therapeutics Inc

20.82

0.15 (0.73%)

Pre Market

Last Updated: 22:00:04

Delayed by 15 minutes

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Celldex Therapeutics Charts.

Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Celldex Therapeutics Charts.

Celldex Therapeutics Inc News

Celldex Therapeutics to Present at Upcoming Investor Conferences
Wednesday 5 March 2025 (6 days ago) • GlobeNewswire Inc.

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025
Tuesday 4 March 2025 (7 days ago) • GlobeNewswire Inc.

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
Sunday 2 March 2025 (1 week ago) • GlobeNewswire Inc.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Friday 28 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 28 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update
Friday 28 February 2025 (2 weeks ago) • GlobeNewswire Inc.

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Saturday 15 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis
Friday 20 December 2024 (3 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 21 November 2024 (4 months ago) • Edgar (US Regulatory)

Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
Thursday 21 November 2024 (4 months ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 15 November 2024 (4 months ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 15 November 2024 (4 months ago) • Edgar (US Regulatory)

More Celldex Therapeutics Inc News Articles

Lindsell Train Investment

Vontobel Financial Produ...

Exchange Traded Fund Ivz...

Invesco Goldman Sachs Eq...

Nabriva Therapeutics (CE)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions